This video is sponsored by the Duke Clinical Medical Series.
Peter Berger, MD and Steven Steinhubl, MD have indicated that the following off-label,
experimental, and/or investigational use of a drug was discussed in the presentaiton: use
of Clopidogrel during percutaneous coronary intervention. The moderator, Peter Berger, MD,
has indicated that he receives research/grant support from Aventis, Conor, Guilford,
Lumen, and Velocimed. Dr. Berger is also a member of an advisory board for Genentech and
Cordis/Johnson & Johnson; he has spoken at scientific symposia for Aventis,
Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also serves as Medical Director
and has equity with Lumen, Inc.
The guest, Steven R. Steinhubl, MD, has nothing to disclose regarding this CME activity.
|
|